ARVN News and Press, Arvinas Inc.

2026-03-10 17:30:17 ET Arvinas, Inc. (ARVN) Barclays 28th Annual Global Healthcare Conference March 10, 2026 11:00 AM EDT... Read the full article on Seeking Alpha For further details see: Arvinas, Inc. (ARVN) Presents at Barclays 28th Annual Global Healthcare Conference Tra...

2026-02-24 17:38:43 ET More on Arvinas Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript Arvinas appoints new president and CEO; leadership transition announced Seeking Alpha’s Quant Rating on Arvinas Historical earnings data for Arvinas Fi...

2026-02-24 17:37:55 ET Arvinas, Inc. (ARVN) Q4 2025 Earnings Call February 24, 2026 8:00 AM EST Company Participants Jeff Boyle - Vice President of Investor Relations Randy Teel - CEO, President & Director Noah Berkowitz - Chief Medical Officer Angela Cac...

2026-02-24 14:15:03 ET Wedbush analyst issues NEUTRAL recommendation for ARVN on February 24, 2026 07:02PM ET. The previous analyst recommendation was Neutral. ARVN was trading at $12.005 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cu...

2026-02-24 14:00:24 ET Image source: The Motley Fool. Tuesday, Feb. 24, 2026, at 8 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-24 07:07:36 ET More on Arvinas Arvinas appoints new president and CEO; leadership transition announced Seeking Alpha’s Quant Rating on Arvinas Historical earnings data for Arvinas Financial information for Arvinas Read the full articl...

– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash runway into second half of 2028 – – ARV-102 (LRRK2) Phase 1 clinical data in patients with Parkinson’s dis...

Interface Inc. (TILE) is expected to report $0.4 for Q4 2025 Evolent Health Inc Class A (EVH) is expected to report $-0.03 for Q4 2025 MercadoLibre Inc. (MELI) is expected to report $11.77 for Q4 2025 Clean Energy Fuels Corp. (CLNE) is expected to report $-0.1 for Q4 2025 Kiniksa ...

2026-02-23 11:48:08 ET More on Arvinas Arvinas appoints new president and CEO; leadership transition announced Seeking Alpha’s Quant Rating on Arvinas Historical earnings data for Arvinas Financial information for Arvinas Read the full articl...

NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide...